z-logo
Premium
Comparison of irbesartan versus atorvastatin therapy on angiotensin II (ANG II)‐induced venoconstriction and plasma levels of angiotensin‐(1–7)[ANG‐(1–7)] in healthy volunteers
Author(s) -
Schindler C.,
Brosnihan K. B.,
Ferrario C. M.,
Kirch W.
Publication year - 2005
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2004.11.045
Subject(s) - angiotensin ii , irbesartan , medicine , renin–angiotensin system , endocrinology , vasodilation , atorvastatin , histamine , pharmacology , receptor , blood pressure
Aim Experimental studies suggest interactions of statins with the renin‐angiotensin‐aldosterone‐system.[Ang‐(1–7)], the most pleiotropic metabolite of angiotensin II functions as a vasodilator by releasing prostaglandins and stimulating NO release. Methods In a randomized double blind double crossover study (n=8) we compared the effects of 30 days systemic therapy with irbesartan (150 mg; IRB) versus atorvastatin (20 mg; STAT) on Ang II‐ induced venoconstriction, endothelium dependent histamine and endothelium independent glyceroltrinitrate[GTN]‐induced dilation by the dorsal hand vein compliance method. Systemic treatments were separated by a 30 day washout period. Results Constant infusion of Ang II caused rapid venous desensitization that peaked after 8 minutes of infusion. Ang II‐induced constriction was 51±25% basal vein size (BVS) before and 36±28% BVS after 30 days of statin treatment (p=0.16) compared to 50±23% before vs 85±26% BVS after initiation of IRB treatment (p=0.012). There was no difference in histamine‐ and GTN‐induced dilation between treatments. Ang II‐levels were 26±13 before and 31±11 pg/mL after STAT (p=n.s.) and 35±12 before vs 329±285 pg/mL after IRB (p=0.02). Ang 1–7 levels were 9±6 before vs 11±9 pg/mL after STAT (p=n.s.) and 10±8 before vs 35±16 pg/mL after IRB (p=0.01). Conclusion A differential effect of STAT and IRB on venous compliance and plasma angiotensins in healthy volunteers suggests a venodilator action of[Ang‐(1–7)] following AT 1 ‐blockade. Clinical Pharmacology & Therapeutics (2005) 77 , P11–P11; doi: 10.1016/j.clpt.2004.11.045

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom